GlassScriptPhysician profile
Jan H Merman
NPI 1578650016
$2,686.97
in general payments reported to CMS, 2019-2025
23 companies · $310 in 2025
The $310 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $409 · 2021: $536 · 2022: $382 · 2023: $432 · 2024: $298 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,040.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $744.53 | 2021-2025 | |
| Amgen INC. | $555.79 | 2019-2022 | |
| Pfizer INC. | $495.99 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $103.71 | 2020-2021 | |
| Lilly USA, LLC | $86.46 | 2019-2024 | Emgality |
| Supernus Pharmaceuticals, INC. | $82.99 | 2019-2020 | |
| Biogen, INC. | $75.62 | 2021-2022 | |
| Allergan, INC. | $75.16 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $64.80 | 2022 | |
| Ucb, INC. | $54.51 | 2021 | |
| Abbott Laboratories | $47.20 | 2021-2025 | Infinity |
| Emd Serono, INC. | $42.30 | 2019 | |
| Harmony Biosciences LLC | $34.42 | 2023 | Wakix |
| Cycle Pharmaceuticals INC | $28.99 | 2025 | Bafiertam, Tascenso Odt |
| Sunovion Pharmaceuticals INC. | $28.03 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $24.19 | 2019 | |
| Arbor Pharmaceuticals, INC. | $24.09 | 2022 | |
| Upsher-Smith Laboratories LLC | $22.68 | 2019 | |
| Tanabe Pharma America, INC. | $22.50 | 2025 | Radicava |
| Catalyst Pharmaceuticals, INC. | $21.56 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $20.00 | 2021 | |
| Csl Behring | $16.43 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Merman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.